Rohan Garje, MD

Associate Professor, Chief of Genitourinary Medical Oncology, Miami Cancer Institute, Baptist Health

[chadi nabhan MD, MBA, FACP @chadinabhan]

Great conversations always with my dear friend @BrainTumorDoc on science at #ASCO26 @ASCO and much more. @BaptistHealthSF is thriving under your leadership.

[Herbert Wertheim Cancer Institute Research @MiamiCancerInst]

New data from @ASTRO_org #MRPTS26 presented by @Ganiyani_MD & @RohanGarjeMD reinforce the promise of 177Lu-PSMA-617 in advanced prostate cancer, showing a consistent ability to delay disease progression across randomized trials. Learn More 👇
https://t.co/yrX2pvfmc9

[Rohan Garje, MD @RohanGarjeMD]

@ZakhariaYousef @MayoClinic @MayoCancerCare Hearty congratulations Yousef! So well deserved! Best wishes

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit https://t.co/4riSVk7AQy to learn more about the candidates and place your vote! Thank you!!

[David H Aggen, MD PhD @Dr_Aggen]

🎶 Wondering how to tackle variant histologies in bladder cancer?

Think of them as music genres—same stage, different openers (neoadj.) and headliners (1st line tx).

🎤 From micropapillary to plasmacytoid—each has a style & strategy.

🎧 Watch here ⬇️
@Uromigos @Dr_Aggen @BladderCancerUS
#BladderCancer #UroOnc #GUonc #PathTwitter

[R. Bryan Rumble @BryanRumble]

@ASCO Guideline Clinical Insights: Systemic therapy in mCRPC, released Sept 4, 2025. Thanks to @rohangarjeMD, Dr. Rahul Parikh, @IrbazRiaz, and Dr. Arsalan Naqvi for their leadership on this article.

[Oncology News Central @OncNewsCentral]

@ASCO updates #mCRPC guidelines for the first time in 10 years. Emphasis on individualized care, ongoing ADT, & #BiomarkerTesting. Key trials include MAGNITUDE, TALAPRO-2, and PROpel. @RohanGarjeMD: “This represents a shift toward #PrecisionOncology.” https://t.co/LfoK56eP5R

[Rohan Garje, MD @RohanGarjeMD]

@ZakhariaYousef @UIowaCancer @MiamiCancerInst @uihealthcare It indeed takes a village to execute clinical trials! Thanks @ZakhariaYousef for your support and mentorship!

[Rohan Garje, MD @RohanGarjeMD]

@PGrivasMDPhD @eaonc @fredhutch @HutchPresident @nicoleflemingmd @HsiehLab @jrgralow @CliffordHudis @lynn_schuchter @NaomiHaas5 Congratulations!

[OncoDaily @oncodaily]

The Updated ASCO Guidelines on Metastatic Castration-Resistant Prostate Cancer - @RohanGarjeMD
@BryanRumble @ASCO

https://t.co/G4KZKRZmb6

#Cancer #OncoDaily #Oncology #GlobalAwareness #FightAgainstCancer #CancerWorld #ASCO #mCRPC

[Dr. Estela Rodriguez @Latinamd]

📣Out now #ASCOGuidelines Update: Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update | Journal of Clinical Oncology https://t.co/3BBBspaeK2 #pcsm @ASCO @RohanGarjeMD

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
@ASCO Guideline Update

https://t.co/tkHjygAGjP

The updated ASCO guideline provides evidence-based recommendations for the systemic treatment of patients with metastatic castration-resistant #ProstateCancer (mCRPC). Therapeutic options with demonstrated overall survival benefit include androgen receptor pathway inhibitors (ARPIs), 💊PARP inhibitors, chemotherapy (docetaxel, cabazitaxel), radiopharmaceuticals ☢️(radium-223, 177Lu-PSMA-617), and sipuleucel-T. For patients with BRCA1/2 alterations, ARPI–PARP inhibitor combinations or PARP inhibitor monotherapy are recommended based on prior treatments. Continued androgen-deprivation therapy, early somatic genetic testing, 🦴bone-protective agents for patients with bone metastases, and palliative care are advised. Treatment selection should be guided by prior systemic therapies, although optimal sequencing remains unclear.

@RohanGarjeMD @IrbazRiaz @SyedArsalanN @BryanRumble @TiansterZhang @katy_beckermann @NehaVapiwala @sebastienhotte @arnabguonc @AlanBryce9 @lisabodei @DrAndrewLoblaw @HamidEmamekhoo @thomashopemd @M_Hassan_Murad @hongfangliu
Ping
@Silke_Gillessen @AOmlin
@nataliagandur @bavilima

[Rohan Garje, MD @RohanGarjeMD]

🚨 New @ASCO Guideline on #mCRPC just published!
Glad to co-author recs on sequencing, #PARP inhibitors, #genomics, chemo & radiopharmaceuticals
Grateful to expert panel
@BryanRumble @IrbazRiaz #RahulParikh @AlanBryce9 @JCO_ASCO @OncoAlert @OncLive
🔗https://t.co/eDA6j6VewH

[Yüksel Ürün @DrYukselUrun]

ASCO 2024 mCRPC Update:
🙌 Put patients first: tailor to comorbidities, life expectancy & access
🧬 Genomic testing (BRCA1/2, HRR, MSI, TMB) = must
🧬 PARP inhibitors: for BRCA1/2, maybe others
☢️ Lu-PSMA: for PSMA+ after ARPI & chemo
❌ No ARPI after ARPI—unless no options
#ProstateCancer #mCRPC #ASCO24 #Oncology #PrecisionMedicine
@ASCO @JCO_ASCO @APCCC_Lugano @OncoAlert @RohanGarjeMD @IrbazRiaz @TiansterZhang @katy_beckermann @NehaVapiwala @PCFnews @Larvol @OncBrothers
https://t.co/We1OEfVd06

[Rohan Garje, MD @RohanGarjeMD]

@PGrivasMDPhD @ASCO @ASCOPres @lynn_schuchter @jrgralow @CliffordHudis @HutchPresident @nicoleflemingmd @OncoAlert @fredhutch @UWMedicine @rarengan @DanLinMD Congratulations @PGrivasMDPhD !

[FDA Oncology @FDAOncology]

FDA expands the indication for a treatment for metastatic castration-resistant prostate cancer
https://t.co/lvAmVkZ1jR

[Zach Klaassen @zklaassen_md]

If you can get it (especially in 🇺🇸), can't argue with the cost of BCG: 1 yr, $1800 👇

#EAU25 debate -- @GGiannarini making the point that BCG is still the best option for HR NMIBC @urotoday

Discussing @EUplatinum paper from Scilipoti, @UroMoschini @UrogerliMD @spsutkaMD @UroDocAsh et al.

[Rohan Garje, MD @RohanGarjeMD]

@apolo_andrea @SaadAtiq24 @DrAndreKydd @theNCI @NIH @NIHClinicalCntr @IRPatNIH @ALLIANCE_org @BladderCancerUS Congratulations!!

[Rohan Garje, MD @RohanGarjeMD]

@PGrivasMDPhD @eaonc @NaomiHaas5 @MonikaJoshimd @fredhutch @HutchPresident @nicoleflemingmd @OncoAlert Congratulations @PGrivasMDPhD !

[Pedro C Barata, MD MSc FACP @PBarataMD]

@binaytara @UHhospitals @maughanonc @huntsmancancer @WinshipAtEmory @bilenma @ZakhariaYousef @arnabguonc @kansalrohit69 @RohanGarjeMD @CParkMD in the room already thinking of the next trial in GU tumors